Q-omics provides the consensus-scored TIGD7 profile across patient tissues and cancer cell-line models. TIGD7 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TIGD7 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TIGD7 RNA expression shows 20,997 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, THCA, and UVM as cancer lineages where TIGD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIGD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIGD7 survival associations across molecular data types. TIGD7 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIGD7 RNA expression–survival associations across cancer types. High TIGD7 expression shows unfavorable associations in UCEC, KIRP and ACC, but favorable associations in UCS, HNSC and CESC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for TIGD7 RNA expression.
This table summarizes TIGD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TIGD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIGD7 shows lower tumor expression in THCA and UCEC and higher tumor expression in LIHC, HNSC, BRCA and CHOL. The THCA box plot shows higher TIGD7 RNA expression in normal versus tumor tissue (log2 FC = −1.163, t-test p < 0.001).
This table shows molecular features associated with TIGD7 in patient tissues and cancer cell lines. In patient samples, TIGD7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TIGD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
